Funding
- Public FundsRetos-Colaboración - 2017 (RTC-2017-5867-1)- 2019 (RTC-2019-6825-1)CDTI 2017 (IDI-20180106)
- Retos-Desarrollo - 2014 (RTC-2014-2412)- 2016 (RTC-2016-5686)Innpacto 2012 (PT-2012-0561-010000)Torres Quevedo - 2012, 2013, 2014, 2015, 2017, 2018
- AMMIC Project / RIS3CAT 2016-2020
- RD14-1-0114 Desenvolupament MIN-102
- Innovative SME
- ENISA Jóvenes Emprendedores 2012
- TECNIOspring PLUS
Aquest projecte ha rebut finançament del programa de recerca i innovació Horitzó 2020 de la Unió Europea sota l'acord de subvenció Marie Skłodowska-Curie No 712949 (TECNIOspring PLUS), així com de l'Agència per a la Competitivitat de l'Empresa de la Generalitat de Catalunya
- The NEXUS trial received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No No. 822968
- NewsSee allMinoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in EuropeMinoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD)Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapyAdditional data from Minoryx’s Phase 2/3 ADVANCE clinical trial presented at American Neurological Association (ANA) 2021Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journalMinoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual MeetingMinoryx presents topline results from Phase 2/3 “ADVANCE” study demonstrating significant clinical benefit of leriglitazone in adrenomyeloneuropathy (AMN)Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxiaMinoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease JournalEuropean Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases
